Exicure, inc. announces receipt of nasdaq notice of non-compliance and implementation of one-for-thirty reverse stock split

Chicago--(business wire)--exicure, inc. (nasdaq: xcur), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting rna to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. edt today, the company's common stock will begin trading on a split-adjusted basis on nasdaq effective with the open of business to
XCUR Ratings Summary
XCUR Quant Ranking